Azathioprine, a genotoxic agent to be considered non-genotoxic in man.
Azathioprine, an immunosuppressive drug, has been used for 25 years. Azathioprine is rapidly converted into a number of metabolites after absorption. Maximum blood levels in experimental animals (mice) were 11.3 micrograms/ml after a dosage of 33.3 mg/kg. Generally, levels of less than 1 microgram/ml are found. As azathioprine is ineffective in hypoxanthine guanine phosphoribosyltransferase (HPRT)-deficient patients, it will be clear that for immunosuppressive activity azathioprine must be metabolised. Regarding mutagenic activity, its mutagenicity for bacteria seems irrelevant for man because the nitroimidazole moiety can be reduced by bacteria but not or hardly at all by mammalian tissues. So 6-mercaptopurine (a metabolite of azathioprine) and its metabolites should be regarded as the active compounds. In vitro azathioprine can induce chromosome aberrations and other cytogenetic events at high, non-physiological doses. However, in view of the low blood levels it is unlikely that azathioprine can induce chromosome aberrations in kidney transplant patients. It is more probable that azathioprine inhibits the elimination of such aberrant cells through its immunosuppressive activity. It should be pointed out that in microbial mutagenicity systems also, azathioprine concentrations that are not reached in patients are needed to obtain an increased mutation rate.
Voogd
C E
CE
National Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands.
D000818:Animals; D001379:Azathioprine / Q000494:pharmacology / Q000633:toxicity*; D002273:Carcinogens; D006801:Humans; D009152:Mutagenicity Tests; D009153:Mutagens; D009154:Mutation; D013723:Teratogens
D002273:Carcinogens; D009153:Mutagens; D013723:Teratogens; D001379:Azathioprine